光子计数CT术前评估乳腺癌:与钼靶、MRI及PET/CT对比
前瞻性研究纳入126例BI-RADS 4C及以上的乳腺癌女性,比较PCCT与MRI、FFDM及18F-FDG PET/CT的表现。PCCT在病灶定性与额外病灶检出方面与MRI相当,评估淋巴结转移优于MRI,但对微钙化检出有限。
要点
- PCCT对额外病灶的敏感度高于FFDM,差值为44%(95%CI:19,66),与MRI接近。
- PCCT评估淋巴结转移的敏感度和准确度均优于MRI,差值分别为10%和6%。
- PCCT会漏掉44%(95%CI:27,52)的微钙化,报告时需结合FFDM。
核心结论
- PCCT对病灶定性和额外病灶检出与MRI表现相近,评估淋巴结转移优于MRI,但检出微钙化能力有限。
研究设计与样本
- 前瞻性研究,纳入126例BI-RADS 4C及以上的女性乳腺癌患者,平均年龄58.1岁±12.3。
- 所有参与者接受乳腺MRI和多期相增强PCCT,局部晚期亚组接受18F-FDG PET/CT。
- 四名放射科医生独立评估病灶形态、额外发现和临床TNM分期,以病理检查为参考标准。
关键影像表现/征象
- 44%(95%CI:27,52)的微钙化在PCCT上被漏检,而FFDM可以显示这些微钙化。
- PCCT检出的两处远处转移与18F-FDG PET/CT及病理结果一致。
诊断标准与关键数值
- PCCT与MRI对病灶定性的κ值为0.57–0.96,对临床T分期的κ值为0.86–0.88。
- PCCT与病理大小的一致性最高,ICC为0.70–0.81。
- 对46个经病理证实的额外病灶,PCCT较FFDM敏感度差值44%(95%CI:19,66),与MRI差值7%(95%CI:-5,21)。
- 对经病理证实的淋巴结转移,PCCT较MRI敏感度差值10%(95%CI:1,20),准确度差值6%(95%CI:1,11)。
- 对临床N分期,PCCT与PET/CT的κ值为0.82(95%CI:0.62,0.96),n=19。
临床应用与阅片要点
- PCCT可同时评估乳腺病灶、腋窝淋巴结及远处转移,减少多次检查。
- 因PCCT对微钙化检出明显受限,不能单独用于乳腺癌筛查或取代FFDM。
- 解读PCCT乳腺图像时应结合FFDM,避免漏诊仅表现为微钙化的病变。
局限性
- 研究为单中心前瞻性设计,样本量126例,PET/CT仅用于局部晚期亚组(n=19)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Photon-counting CT (PCCT) offers improved spatial resolution, contrast to noise ratio, and dose efficiency, but its clinical utility remains incompletely defined for breast cancer. Purpose To evaluate the feasibility of PCCT for pretreatment breast cancer assessment through comparisons with MRI, full-field digital mammography (FFDM), and fluorine 18 (18F) fluorodeoxyglucose (FDG) PET/CT. Materials and Methods In this prospective study (March-May 2025), female participants with breast lesions categorized as Breast Imaging Reporting and Data System 4C or higher at US or FFDM underwent breast MRI and multiphasic contrast-enhanced PCCT. 18F-FDG PET/CT was performed in a subset with locally advanced disease. Four radiologists independently evaluated lesion morphologic characteristics, additional findings, and clinical TNM stage. Agreement was analyzed using intraclass correlation coefficients (ICCs) and κ statistics. The diagnostic performance for additional lesions and nodal metastasis was compared with the reference standard (pathologic examination). Results Among 126 participants (mean age, 58.1 years ± 12.3 [SD]), interreader agreement across PCCT, MRI, and FFDM was good to excellent. PCCT agreed with MRI for lesion characterization (κ = 0.57-0.96) and clinical T categorization (κ = 0.86-0.88), with highest agreement with pathologic size (ICC, 0.70-0.81). For 46 pathologically confirmed additional lesions, PCCT was more sensitive than FFDM (difference, 44% [95% CI: 19, 66]) and similar to MRI (difference, 7% [95% CI: -5, 21]). Additionally, 44% (95% CI: 27, 52) of microcalcifications were missed at PCCT versus FFDM. For pathologically confirmed nodal metastasis, PCCT was more sensitive (difference, 10% [95% CI: 1, 20]) and accurate (difference, 6% [95% CI: 1, 11]) than MRI. For clinical N category, PCCT agreed with PET/CT (κ = 0.82 [95% CI: 0.62, 0.96]; n = 19). Two distant metastases identified at PCCT were consistent with 18F-FDG PET/CT and pathologic findings. Conclusion PCCT demonstrated similar performance to MRI for lesion characterization and detection of additional lesions, with better performance for nodal metastasis evaluation; however, detection of microcalcifications was limited. © RSNA, 2026 Supplemental material is available for this article.
引用
- Fu, Zeng, Chang, et al. Performance of Photon-counting CT for Assessing Pretreatment Breast Cancer: Comparison with Mammography, MRI, and 18F-FDG PET/CT. Radiology. 2026. PMID: 42678255. doi:10.1148/radiol.253531
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。